Did you like this article? Please share it.
Collaborations speed up innovation. InterAx Biotech AG, a spin-off of the Paul Scherrer Institute (PSI) and ETH Zurich, based at PARK INNOVAARE, and Professor Peter Kolb from the University of Marburg are working together to develop lead compounds with highly tailored pharmacological properties for an undisclosed target.
InterAx Biotech AG is developing a unique drug discovery platform for identifying functionally selective G protein-coupled receptor (GPCR) drug candidates. What makes InterAx unique is its combination of protein-based IP-protected biosensors and mathematical modeling of signaling pathways.
Recently, the company announced a new collaboration with Professor Peter Kolb, a group leader in the Department of Pharmaceutical Chemistry research at the University of Marburg. By combining Prof. Kolb’s unique expertise in virtual screening with the InterAx biosensor and systems biology platform, the company will establish an iterative design and testing cycle that will help guide the optimization of initial hits towards potent and efficacious lead matter. At the same time, the company and the University will be defining potentially paradigm-changing principles.